Characterization of the components in plasma EVs unveiling the link between EVs-derived complement C3 with the severity and initial treatment response of profound sudden sensorineural hearing loss
•The differential expression of proteins and miRNAs in plasma EVs of profound SSNHL patients and the related biological function was identified.•Complement C3 is one of the most significant proteins with differentially expressed in plasma EVs of profound SSNHL patients.•Plasma EVs-derived complement...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2024-11, Vol.141, p.112944, Article 112944 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 112944 |
| container_title | International immunopharmacology |
| container_volume | 141 |
| creator | Chen, Hui-Ting Yi, Ying Huang, Wan-Yi Wu, Min-Yu Xiong, Qin Wang, Xian-Ren Liu, Min Wu, Xuan Jiang, Guang-Li Zhuang, Hui-Wen Chen, Kai-Tian Xiong, Guan-Xia Fang, Shu-Bin |
| description | •The differential expression of proteins and miRNAs in plasma EVs of profound SSNHL patients and the related biological function was identified.•Complement C3 is one of the most significant proteins with differentially expressed in plasma EVs of profound SSNHL patients.•Plasma EVs-derived complement C3 is associated with the severity and early efficacy of profound SSNHL patients.
Sudden sensorineural hearing loss (SSNHL) is characterized by rapid, unexplained loss of hearing within a 72-hour period and exhibits a high incidence globally. Despite this, the outcomes of therapeutic interventions remain largely unpredictable, especially for those with profound hearing loss. Extracellular vesicles (EVs), nano-sized entities containing biological materials, are implicated in the development of numerous diseases. The specific relationship between EVs and both the severity and treatment effectiveness of SSNHL, however, is not well understood.
This study involved the analysis of medical records from the Department of Otolaryngology (September 1, 2020 − December 31, 2022) of patients diagnosed with SSNHL according to the 2015 Guidelines for Diagnosis and Treatment of Sudden Deafness in China. Peripheral blood samples from patients with various types of SSNHL before and after treatment were collected, alongside samples from healthy volunteers serving as controls. Plasma EVs were isolated using gel rejection chromatography and analyzed for concentration, marker presence, and morphology using Nanosight, Western blot, and transmission electron microscopy (TEM), respectively. Proteomics and miRNA assessments were conducted to identify differentially expressed proteins and miRNAs in the plasma EVs of SSNHL patients and healthy volunteers. Key proteins were further validated through Western blot analysis. Enzyme-linked immunosorbent assay (ELISA) was utilized to determine the levels of complement C3 in plasma EVs, and correlation analyses were performed with audiological data pre- and post-treatment.
Plasma from SSNHL patients of varying types was collected and their EVs were successfully isolated and characterized. Proteomic analysis revealed that complement C3 levels in the plasma EVs of patients with profound SSNHL were significantly higher compared to healthy controls. Differential expression of miRNAs in plasma EVs and their related functions were also identified. The study found that the level of complement C3 in plasma EVs, but not the total plasma complement C3, po |
| doi_str_mv | 10.1016/j.intimp.2024.112944 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3094044927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576924014656</els_id><sourcerecordid>3094044927</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-5b6cb1ed3acb06fe611ab1cc7a42dd5846025c524241e6706c1522b09e16373c3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEoqXwBgh5ySaD_zPZIKFRaZEqdUO7tRz7hvGQ2MF2pirPx4PhTArLrnxlf-fcY52qek_whmAiPx02zmc3ThuKKd8QQlvOX1TnZNtsa9Jg8bLMQja1aGR7Vr1J6YBxuefkdXXGWiIYw9vz6s9ur6M2GaL7rbMLHoUe5T0gE8YpePA5IefRNOg0anR5n9Dsj-AG53-csDL8RB3kBwC_PNe2OB3BnvQDjMUA7Rh6cHl_4hMcC5Afkfa2GLvs9IByBJ1PaIRUtiZYUkwx9GEuWJqtLe4JfArReZhj0exBxyXEEFJ6W73q9ZDg3dN5Ud19vfy-u65vbq--7b7c1IZykmvRSdMRsEybDsseJCG6I8Y0mlNrxZZLTIURlBcaZIOlIYLSDrdAJGuYYRfVx9W3RPs1Q8pqdMnAMGgPYU6K4ZZjzlvaFJSvqIklYIReTdGNOj4qgtXSnzqotT-19KfW_orsw9OGuRvB_hf9K6wAn1cAyj-PDqJKxoE3YF0Ek5UN7vkNfwEA5rMS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3094044927</pqid></control><display><type>article</type><title>Characterization of the components in plasma EVs unveiling the link between EVs-derived complement C3 with the severity and initial treatment response of profound sudden sensorineural hearing loss</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chen, Hui-Ting ; Yi, Ying ; Huang, Wan-Yi ; Wu, Min-Yu ; Xiong, Qin ; Wang, Xian-Ren ; Liu, Min ; Wu, Xuan ; Jiang, Guang-Li ; Zhuang, Hui-Wen ; Chen, Kai-Tian ; Xiong, Guan-Xia ; Fang, Shu-Bin</creator><creatorcontrib>Chen, Hui-Ting ; Yi, Ying ; Huang, Wan-Yi ; Wu, Min-Yu ; Xiong, Qin ; Wang, Xian-Ren ; Liu, Min ; Wu, Xuan ; Jiang, Guang-Li ; Zhuang, Hui-Wen ; Chen, Kai-Tian ; Xiong, Guan-Xia ; Fang, Shu-Bin</creatorcontrib><description>•The differential expression of proteins and miRNAs in plasma EVs of profound SSNHL patients and the related biological function was identified.•Complement C3 is one of the most significant proteins with differentially expressed in plasma EVs of profound SSNHL patients.•Plasma EVs-derived complement C3 is associated with the severity and early efficacy of profound SSNHL patients.
Sudden sensorineural hearing loss (SSNHL) is characterized by rapid, unexplained loss of hearing within a 72-hour period and exhibits a high incidence globally. Despite this, the outcomes of therapeutic interventions remain largely unpredictable, especially for those with profound hearing loss. Extracellular vesicles (EVs), nano-sized entities containing biological materials, are implicated in the development of numerous diseases. The specific relationship between EVs and both the severity and treatment effectiveness of SSNHL, however, is not well understood.
This study involved the analysis of medical records from the Department of Otolaryngology (September 1, 2020 − December 31, 2022) of patients diagnosed with SSNHL according to the 2015 Guidelines for Diagnosis and Treatment of Sudden Deafness in China. Peripheral blood samples from patients with various types of SSNHL before and after treatment were collected, alongside samples from healthy volunteers serving as controls. Plasma EVs were isolated using gel rejection chromatography and analyzed for concentration, marker presence, and morphology using Nanosight, Western blot, and transmission electron microscopy (TEM), respectively. Proteomics and miRNA assessments were conducted to identify differentially expressed proteins and miRNAs in the plasma EVs of SSNHL patients and healthy volunteers. Key proteins were further validated through Western blot analysis. Enzyme-linked immunosorbent assay (ELISA) was utilized to determine the levels of complement C3 in plasma EVs, and correlation analyses were performed with audiological data pre- and post-treatment.
Plasma from SSNHL patients of varying types was collected and their EVs were successfully isolated and characterized. Proteomic analysis revealed that complement C3 levels in the plasma EVs of patients with profound SSNHL were significantly higher compared to healthy controls. Differential expression of miRNAs in plasma EVs and their related functions were also identified. The study found that the level of complement C3 in plasma EVs, but not the total plasma complement C3, positively correlated with the severity of SSNHL in patients exhibiting positive therapeutic responses, particularly in those with initially lower levels of EV-associated complement C3. After treatment, complement C3 level was decreased in patients with initially higher levels of EV-associated complement C3. No significant correlation was observed between changes in plasma EV-derived complement C3 levels and the degree of hearing loss in either responders or non-responders among patients with profound SSNHL.
Differential profiles of proteins and miRNAs were identified in patients with profound SSNHL. Notably, plasma EV-derived complement C3 was linked to both the severity and early treatment effectiveness of patients with profound SSNHL.</description><identifier>ISSN: 1567-5769</identifier><identifier>ISSN: 1878-1705</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2024.112944</identifier><identifier>PMID: 39153308</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Aged ; Biomarkers ; Biomarkers - blood ; Complement C3 ; Complement C3 - metabolism ; Extracellular vesicles ; Extracellular Vesicles - metabolism ; Female ; Hearing Loss, Sensorineural - blood ; Hearing Loss, Sensorineural - diagnosis ; Hearing Loss, Sudden - blood ; Hearing Loss, Sudden - therapy ; Humans ; Male ; MicroRNAs - blood ; Middle Aged ; Proteomics ; Severity of Illness Index ; Sudden sensorineural hearing loss ; Treatment Outcome ; Young Adult</subject><ispartof>International immunopharmacology, 2024-11, Vol.141, p.112944, Article 112944</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-5b6cb1ed3acb06fe611ab1cc7a42dd5846025c524241e6706c1522b09e16373c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576924014656$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39153308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Hui-Ting</creatorcontrib><creatorcontrib>Yi, Ying</creatorcontrib><creatorcontrib>Huang, Wan-Yi</creatorcontrib><creatorcontrib>Wu, Min-Yu</creatorcontrib><creatorcontrib>Xiong, Qin</creatorcontrib><creatorcontrib>Wang, Xian-Ren</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Wu, Xuan</creatorcontrib><creatorcontrib>Jiang, Guang-Li</creatorcontrib><creatorcontrib>Zhuang, Hui-Wen</creatorcontrib><creatorcontrib>Chen, Kai-Tian</creatorcontrib><creatorcontrib>Xiong, Guan-Xia</creatorcontrib><creatorcontrib>Fang, Shu-Bin</creatorcontrib><title>Characterization of the components in plasma EVs unveiling the link between EVs-derived complement C3 with the severity and initial treatment response of profound sudden sensorineural hearing loss</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•The differential expression of proteins and miRNAs in plasma EVs of profound SSNHL patients and the related biological function was identified.•Complement C3 is one of the most significant proteins with differentially expressed in plasma EVs of profound SSNHL patients.•Plasma EVs-derived complement C3 is associated with the severity and early efficacy of profound SSNHL patients.
Sudden sensorineural hearing loss (SSNHL) is characterized by rapid, unexplained loss of hearing within a 72-hour period and exhibits a high incidence globally. Despite this, the outcomes of therapeutic interventions remain largely unpredictable, especially for those with profound hearing loss. Extracellular vesicles (EVs), nano-sized entities containing biological materials, are implicated in the development of numerous diseases. The specific relationship between EVs and both the severity and treatment effectiveness of SSNHL, however, is not well understood.
This study involved the analysis of medical records from the Department of Otolaryngology (September 1, 2020 − December 31, 2022) of patients diagnosed with SSNHL according to the 2015 Guidelines for Diagnosis and Treatment of Sudden Deafness in China. Peripheral blood samples from patients with various types of SSNHL before and after treatment were collected, alongside samples from healthy volunteers serving as controls. Plasma EVs were isolated using gel rejection chromatography and analyzed for concentration, marker presence, and morphology using Nanosight, Western blot, and transmission electron microscopy (TEM), respectively. Proteomics and miRNA assessments were conducted to identify differentially expressed proteins and miRNAs in the plasma EVs of SSNHL patients and healthy volunteers. Key proteins were further validated through Western blot analysis. Enzyme-linked immunosorbent assay (ELISA) was utilized to determine the levels of complement C3 in plasma EVs, and correlation analyses were performed with audiological data pre- and post-treatment.
Plasma from SSNHL patients of varying types was collected and their EVs were successfully isolated and characterized. Proteomic analysis revealed that complement C3 levels in the plasma EVs of patients with profound SSNHL were significantly higher compared to healthy controls. Differential expression of miRNAs in plasma EVs and their related functions were also identified. The study found that the level of complement C3 in plasma EVs, but not the total plasma complement C3, positively correlated with the severity of SSNHL in patients exhibiting positive therapeutic responses, particularly in those with initially lower levels of EV-associated complement C3. After treatment, complement C3 level was decreased in patients with initially higher levels of EV-associated complement C3. No significant correlation was observed between changes in plasma EV-derived complement C3 levels and the degree of hearing loss in either responders or non-responders among patients with profound SSNHL.
Differential profiles of proteins and miRNAs were identified in patients with profound SSNHL. Notably, plasma EV-derived complement C3 was linked to both the severity and early treatment effectiveness of patients with profound SSNHL.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Complement C3</subject><subject>Complement C3 - metabolism</subject><subject>Extracellular vesicles</subject><subject>Extracellular Vesicles - metabolism</subject><subject>Female</subject><subject>Hearing Loss, Sensorineural - blood</subject><subject>Hearing Loss, Sensorineural - diagnosis</subject><subject>Hearing Loss, Sudden - blood</subject><subject>Hearing Loss, Sudden - therapy</subject><subject>Humans</subject><subject>Male</subject><subject>MicroRNAs - blood</subject><subject>Middle Aged</subject><subject>Proteomics</subject><subject>Severity of Illness Index</subject><subject>Sudden sensorineural hearing loss</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1567-5769</issn><issn>1878-1705</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhSMEoqXwBgh5ySaD_zPZIKFRaZEqdUO7tRz7hvGQ2MF2pirPx4PhTArLrnxlf-fcY52qek_whmAiPx02zmc3ThuKKd8QQlvOX1TnZNtsa9Jg8bLMQja1aGR7Vr1J6YBxuefkdXXGWiIYw9vz6s9ur6M2GaL7rbMLHoUe5T0gE8YpePA5IefRNOg0anR5n9Dsj-AG53-csDL8RB3kBwC_PNe2OB3BnvQDjMUA7Rh6cHl_4hMcC5Afkfa2GLvs9IByBJ1PaIRUtiZYUkwx9GEuWJqtLe4JfArReZhj0exBxyXEEFJ6W73q9ZDg3dN5Ud19vfy-u65vbq--7b7c1IZykmvRSdMRsEybDsseJCG6I8Y0mlNrxZZLTIURlBcaZIOlIYLSDrdAJGuYYRfVx9W3RPs1Q8pqdMnAMGgPYU6K4ZZjzlvaFJSvqIklYIReTdGNOj4qgtXSnzqotT-19KfW_orsw9OGuRvB_hf9K6wAn1cAyj-PDqJKxoE3YF0Ek5UN7vkNfwEA5rMS</recordid><startdate>20241115</startdate><enddate>20241115</enddate><creator>Chen, Hui-Ting</creator><creator>Yi, Ying</creator><creator>Huang, Wan-Yi</creator><creator>Wu, Min-Yu</creator><creator>Xiong, Qin</creator><creator>Wang, Xian-Ren</creator><creator>Liu, Min</creator><creator>Wu, Xuan</creator><creator>Jiang, Guang-Li</creator><creator>Zhuang, Hui-Wen</creator><creator>Chen, Kai-Tian</creator><creator>Xiong, Guan-Xia</creator><creator>Fang, Shu-Bin</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241115</creationdate><title>Characterization of the components in plasma EVs unveiling the link between EVs-derived complement C3 with the severity and initial treatment response of profound sudden sensorineural hearing loss</title><author>Chen, Hui-Ting ; Yi, Ying ; Huang, Wan-Yi ; Wu, Min-Yu ; Xiong, Qin ; Wang, Xian-Ren ; Liu, Min ; Wu, Xuan ; Jiang, Guang-Li ; Zhuang, Hui-Wen ; Chen, Kai-Tian ; Xiong, Guan-Xia ; Fang, Shu-Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-5b6cb1ed3acb06fe611ab1cc7a42dd5846025c524241e6706c1522b09e16373c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Complement C3</topic><topic>Complement C3 - metabolism</topic><topic>Extracellular vesicles</topic><topic>Extracellular Vesicles - metabolism</topic><topic>Female</topic><topic>Hearing Loss, Sensorineural - blood</topic><topic>Hearing Loss, Sensorineural - diagnosis</topic><topic>Hearing Loss, Sudden - blood</topic><topic>Hearing Loss, Sudden - therapy</topic><topic>Humans</topic><topic>Male</topic><topic>MicroRNAs - blood</topic><topic>Middle Aged</topic><topic>Proteomics</topic><topic>Severity of Illness Index</topic><topic>Sudden sensorineural hearing loss</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Hui-Ting</creatorcontrib><creatorcontrib>Yi, Ying</creatorcontrib><creatorcontrib>Huang, Wan-Yi</creatorcontrib><creatorcontrib>Wu, Min-Yu</creatorcontrib><creatorcontrib>Xiong, Qin</creatorcontrib><creatorcontrib>Wang, Xian-Ren</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Wu, Xuan</creatorcontrib><creatorcontrib>Jiang, Guang-Li</creatorcontrib><creatorcontrib>Zhuang, Hui-Wen</creatorcontrib><creatorcontrib>Chen, Kai-Tian</creatorcontrib><creatorcontrib>Xiong, Guan-Xia</creatorcontrib><creatorcontrib>Fang, Shu-Bin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Hui-Ting</au><au>Yi, Ying</au><au>Huang, Wan-Yi</au><au>Wu, Min-Yu</au><au>Xiong, Qin</au><au>Wang, Xian-Ren</au><au>Liu, Min</au><au>Wu, Xuan</au><au>Jiang, Guang-Li</au><au>Zhuang, Hui-Wen</au><au>Chen, Kai-Tian</au><au>Xiong, Guan-Xia</au><au>Fang, Shu-Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of the components in plasma EVs unveiling the link between EVs-derived complement C3 with the severity and initial treatment response of profound sudden sensorineural hearing loss</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2024-11-15</date><risdate>2024</risdate><volume>141</volume><spage>112944</spage><pages>112944-</pages><artnum>112944</artnum><issn>1567-5769</issn><issn>1878-1705</issn><eissn>1878-1705</eissn><abstract>•The differential expression of proteins and miRNAs in plasma EVs of profound SSNHL patients and the related biological function was identified.•Complement C3 is one of the most significant proteins with differentially expressed in plasma EVs of profound SSNHL patients.•Plasma EVs-derived complement C3 is associated with the severity and early efficacy of profound SSNHL patients.
Sudden sensorineural hearing loss (SSNHL) is characterized by rapid, unexplained loss of hearing within a 72-hour period and exhibits a high incidence globally. Despite this, the outcomes of therapeutic interventions remain largely unpredictable, especially for those with profound hearing loss. Extracellular vesicles (EVs), nano-sized entities containing biological materials, are implicated in the development of numerous diseases. The specific relationship between EVs and both the severity and treatment effectiveness of SSNHL, however, is not well understood.
This study involved the analysis of medical records from the Department of Otolaryngology (September 1, 2020 − December 31, 2022) of patients diagnosed with SSNHL according to the 2015 Guidelines for Diagnosis and Treatment of Sudden Deafness in China. Peripheral blood samples from patients with various types of SSNHL before and after treatment were collected, alongside samples from healthy volunteers serving as controls. Plasma EVs were isolated using gel rejection chromatography and analyzed for concentration, marker presence, and morphology using Nanosight, Western blot, and transmission electron microscopy (TEM), respectively. Proteomics and miRNA assessments were conducted to identify differentially expressed proteins and miRNAs in the plasma EVs of SSNHL patients and healthy volunteers. Key proteins were further validated through Western blot analysis. Enzyme-linked immunosorbent assay (ELISA) was utilized to determine the levels of complement C3 in plasma EVs, and correlation analyses were performed with audiological data pre- and post-treatment.
Plasma from SSNHL patients of varying types was collected and their EVs were successfully isolated and characterized. Proteomic analysis revealed that complement C3 levels in the plasma EVs of patients with profound SSNHL were significantly higher compared to healthy controls. Differential expression of miRNAs in plasma EVs and their related functions were also identified. The study found that the level of complement C3 in plasma EVs, but not the total plasma complement C3, positively correlated with the severity of SSNHL in patients exhibiting positive therapeutic responses, particularly in those with initially lower levels of EV-associated complement C3. After treatment, complement C3 level was decreased in patients with initially higher levels of EV-associated complement C3. No significant correlation was observed between changes in plasma EV-derived complement C3 levels and the degree of hearing loss in either responders or non-responders among patients with profound SSNHL.
Differential profiles of proteins and miRNAs were identified in patients with profound SSNHL. Notably, plasma EV-derived complement C3 was linked to both the severity and early treatment effectiveness of patients with profound SSNHL.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39153308</pmid><doi>10.1016/j.intimp.2024.112944</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2024-11, Vol.141, p.112944, Article 112944 |
| issn | 1567-5769 1878-1705 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3094044927 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Biomarkers Biomarkers - blood Complement C3 Complement C3 - metabolism Extracellular vesicles Extracellular Vesicles - metabolism Female Hearing Loss, Sensorineural - blood Hearing Loss, Sensorineural - diagnosis Hearing Loss, Sudden - blood Hearing Loss, Sudden - therapy Humans Male MicroRNAs - blood Middle Aged Proteomics Severity of Illness Index Sudden sensorineural hearing loss Treatment Outcome Young Adult |
| title | Characterization of the components in plasma EVs unveiling the link between EVs-derived complement C3 with the severity and initial treatment response of profound sudden sensorineural hearing loss |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T05%3A45%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20the%20components%20in%20plasma%20EVs%20unveiling%20the%20link%20between%20EVs-derived%20complement%20C3%20with%20the%20severity%20and%20initial%20treatment%20response%20of%20profound%20sudden%20sensorineural%20hearing%20loss&rft.jtitle=International%20immunopharmacology&rft.au=Chen,%20Hui-Ting&rft.date=2024-11-15&rft.volume=141&rft.spage=112944&rft.pages=112944-&rft.artnum=112944&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2024.112944&rft_dat=%3Cproquest_cross%3E3094044927%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3094044927&rft_id=info:pmid/39153308&rft_els_id=S1567576924014656&rfr_iscdi=true |